Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales

Key Takeaways NVS posted Q4 core EPS of $2.03, beating estimates, while revenues rose 1% but missed expectations.NVS sales were pressured by U.S. generic competition for Entresto and Promacta, causing a 1% decline.NVS saw strong Q4 growth from Cosentyx, Kisqali, Pluvicto and Scemblix, partly offsetting headwinds.Swiss pharma giant Novartis AG (NVS) reported fourth-quarter core earnings per share (excluding one-time charges) of $2.03, which beat the Zacks Consensus Estimate of $1.99. The figure was also up f ...